The EVARREST® Fibrin Sealant Patch Liver Study

Completed · Phase 3

Conditions studied: Hemorrhage

In brief

To evaluate the safety and hemostatic effectiveness of EVARREST® Fibrin Sealant Patch (EVARREST) versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.

Key facts

Study ID

NCT01993888

Run by

Ethicon, Inc.

People needed

102

Starts

2013-10-01

Expected to finish

2014-09-01

Last updated by the study team

2016-07-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects ≥ 18 years of age, requiring elective or urgent, open hepatic surgery.
• Presence of an appropriate bleeding hepatic parenchymal Target Bleeding Site (TBS) as identified intra-operatively by the surgeon
• Subjects or legally authorized representatives must be willing to participate in the study, and provide written informed consent. (Note: This criteria does allow for hospital translators to be used where approved by Ethics Committees/Institutional Review Boards)

You may not qualify if…

• Subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedure;
• TBS is from large defects in arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of EVARREST® to blood flow and pressure during healing and absorption of the product;
• TBS with major arterial bleeding requiring suture or mechanical ligation;
• Subjects admitted for trauma surgery;
• Subject is a transplant patient for fulminant hepatic failure
• Subject with TBS within an actively infected field;
• Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine;
• Subjects with known intolerance to blood products or to one of the components of the study product or is unwilling to receive blood products;
• Subjects who are known, current alcohol and / or drug abusers;
• Subjects who have participated in another investigational medical device or investigational drug trial within 30 days of surgery or are expected to participate in another medical device or investigational drug trial during the course of the study;
• Female subjects who are pregnant or nursing.

Where it is running

• Clinical Investigation Site #13 — Birmingham, Alabama, United States
• Clinical Investigation Site #10 — Augusta, Georgia, United States
• Clinical Investigation Site #16 — Chicago, Illinois, United States
• Clinical Investigation Site #12 — Chicago, Illinois, United States
• Clinical Investigation Site #15 — New Orleans, Louisiana, United States
• Clinical Investigation Site #9 — St Louis, Missouri, United States
• Clinical Investigation Site #11 — New York, New York, United States
• Clinical Investigation Site #14 — New York, New York, United States
• Clinical Investigation Site #8 — Philadelphia, Pennsylvania, United States
• Clinical Investigation Site #17 — Pittsburgh, Pennsylvania, United States
• Clinical Investigation Site #3 — Melbourne, Australia
• Clinical Investigation Site #2 — Woodville South, Australia
• Clinical Investigation Site #1 — Auckland, New Zealand
• Clinical Investigation Site #6 — Birmingham, United Kingdom
• Clinical Investigation Site #7 — Cambridge, United Kingdom
• Clinical Investigation Site #4 — Edinburgh, United Kingdom
• Clinical Investigation Site #5 — Leeds, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.